Antiviral properties of 3-quinolinecarboxamides: a series of novel non-nucleoside antiherpetic agents. 1997

M P Wentland, and R B Perni, and P H Dorff, and R P Brundage, and M J Castaldi, and J A Carlson, and T R Bailey, and S C Aldous, and P M Carabateas, and E R Bacon, and R K Kullnig, and D C Young, and M G Woods, and S D Kingsley, and K A Ryan, and D Rosi, and M L Drozd, and F J Dutko
Sterling Winthrop Pharmaceuticals Research Division, Sterling Winthrop Inc., Collegeville, PA 19426-0900, USA.

Novel antiherpetic 3-quinolinecarboxamides were discovered as part of a drug discovery program at Sterling Winthrop Inc. A major goal of this research was to identify novel non-nucleoside agents possessing activity against acyclovir resistant herpes simplex virus. From screening compound libraries in an HSV-2 plaque reduction assay, 1-ethyl-1,4-dihydro-4-oxo-7-(4-pyridinyl)-3-quinolinecarboxamide (1) emerged as an attractive lead structure. By modifying the quinoline ring at the 1-, 2-, 3-, 4-, and 7-positions, analogues were identified that have up to 5-fold increased in vitro potency relative to acyclovir. In a single dose mouse model of infection the 1-(4-FC6H4) analogue 17, one of the most potent derivatives in vitro, displayed comparable oral antiherpetic efficacy to acyclovir at 1/16 the dose; in a multiple dose regimen, however, it was 2-fold less potent. Mechanism of action studies indicate that these new compounds interact with a different, as yet undefined, molecular target than acyclovir.

UI MeSH Term Description Entries
D010948 Viral Plaque Assay Method for measuring viral infectivity and multiplication in CULTURED CELLS. Clear lysed areas or plaques develop as the VIRAL PARTICLES are released from the infected cells during incubation. With some VIRUSES, the cells are killed by a cytopathic effect; with others, the infected cells are not killed but can be detected by their hemadsorptive ability. Sometimes the plaque cells contain VIRAL ANTIGENS which can be measured by IMMUNOFLUORESCENCE. Bacteriophage Plaque Assay,Assay, Bacteriophage Plaque,Assay, Viral Plaque,Assays, Bacteriophage Plaque,Assays, Viral Plaque,Bacteriophage Plaque Assays,Plaque Assay, Bacteriophage,Plaque Assay, Viral,Plaque Assays, Bacteriophage,Plaque Assays, Viral,Viral Plaque Assays
D011804 Quinolines
D002522 Chlorocebus aethiops A species of CERCOPITHECUS containing three subspecies: C. tantalus, C. pygerythrus, and C. sabeus. They are found in the forests and savannah of Africa. The African green monkey is the natural host of SIMIAN IMMUNODEFICIENCY VIRUS and is used in AIDS research. African Green Monkey,Cercopithecus aethiops,Cercopithecus griseoviridis,Cercopithecus griseus,Cercopithecus pygerythrus,Cercopithecus sabeus,Cercopithecus tantalus,Chlorocebus cynosuros,Chlorocebus cynosurus,Chlorocebus pygerythrus,Green Monkey,Grivet Monkey,Lasiopyga weidholzi,Malbrouck,Malbrouck Monkey,Monkey, African Green,Monkey, Green,Monkey, Grivet,Monkey, Vervet,Savanah Monkey,Vervet Monkey,Savannah Monkey,African Green Monkey,Chlorocebus cynosuro,Green Monkey, African,Green Monkeys,Grivet Monkeys,Malbrouck Monkeys,Malbroucks,Monkey, Malbrouck,Monkey, Savanah,Monkey, Savannah,Savannah Monkeys,Vervet Monkeys
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D004353 Drug Evaluation, Preclinical Preclinical testing of drugs in experimental animals or in vitro for their biological and toxic effects and potential clinical applications. Drug Screening,Evaluation Studies, Drug, Pre-Clinical,Drug Evaluation Studies, Preclinical,Drug Evaluations, Preclinical,Evaluation Studies, Drug, Preclinical,Evaluation, Preclinical Drug,Evaluations, Preclinical Drug,Medicinal Plants Testing, Preclinical,Preclinical Drug Evaluation,Preclinical Drug Evaluations,Drug Screenings,Screening, Drug,Screenings, Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000212 Acyclovir A GUANOSINE analog that acts as an antimetabolite. Viruses are especially susceptible. Used especially against herpes. Acycloguanosine,9-((2-Hydroxyethoxy)methyl)guanine,Aci-Sanorania,Acic,Aciclobeta,Aciclostad,Aciclovir,Aciclovir Alonga,Aciclovir-Sanorania,Acifur,Acipen Solutab,Acivir,Activir,Acyclo-V,Acyclovir Sodium,Antiherpes Creme,Avirax,Cicloferon,Clonorax,Cusiviral,Genvir,Herpetad,Herpofug,Herpotern,Herpoviric,Isavir,Laciken,Mapox,Maynar,Milavir,Opthavir,Supraviran,Viclovir,Vipral,Virax-Puren,Virherpes,Virmen,Virolex,Virupos,Virzin,Wellcome-248U,Zoliparin,Zovirax,Zyclir,aciclovir von ct,Aci Sanorania,Aciclovir Sanorania,Acyclo V,Alonga, Aciclovir,Sodium, Acyclovir,Solutab, Acipen,Virax Puren,ViraxPuren,Wellcome 248U,Wellcome248U
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships

Related Publications

M P Wentland, and R B Perni, and P H Dorff, and R P Brundage, and M J Castaldi, and J A Carlson, and T R Bailey, and S C Aldous, and P M Carabateas, and E R Bacon, and R K Kullnig, and D C Young, and M G Woods, and S D Kingsley, and K A Ryan, and D Rosi, and M L Drozd, and F J Dutko
February 1989, Nihon rinsho. Japanese journal of clinical medicine,
M P Wentland, and R B Perni, and P H Dorff, and R P Brundage, and M J Castaldi, and J A Carlson, and T R Bailey, and S C Aldous, and P M Carabateas, and E R Bacon, and R K Kullnig, and D C Young, and M G Woods, and S D Kingsley, and K A Ryan, and D Rosi, and M L Drozd, and F J Dutko
March 2011, Bioorganic & medicinal chemistry letters,
M P Wentland, and R B Perni, and P H Dorff, and R P Brundage, and M J Castaldi, and J A Carlson, and T R Bailey, and S C Aldous, and P M Carabateas, and E R Bacon, and R K Kullnig, and D C Young, and M G Woods, and S D Kingsley, and K A Ryan, and D Rosi, and M L Drozd, and F J Dutko
July 1999, Current medicinal chemistry,
M P Wentland, and R B Perni, and P H Dorff, and R P Brundage, and M J Castaldi, and J A Carlson, and T R Bailey, and S C Aldous, and P M Carabateas, and E R Bacon, and R K Kullnig, and D C Young, and M G Woods, and S D Kingsley, and K A Ryan, and D Rosi, and M L Drozd, and F J Dutko
January 2012, Nucleosides, nucleotides & nucleic acids,
M P Wentland, and R B Perni, and P H Dorff, and R P Brundage, and M J Castaldi, and J A Carlson, and T R Bailey, and S C Aldous, and P M Carabateas, and E R Bacon, and R K Kullnig, and D C Young, and M G Woods, and S D Kingsley, and K A Ryan, and D Rosi, and M L Drozd, and F J Dutko
January 1981, Acta microbiologica Academiae Scientiarum Hungaricae,
M P Wentland, and R B Perni, and P H Dorff, and R P Brundage, and M J Castaldi, and J A Carlson, and T R Bailey, and S C Aldous, and P M Carabateas, and E R Bacon, and R K Kullnig, and D C Young, and M G Woods, and S D Kingsley, and K A Ryan, and D Rosi, and M L Drozd, and F J Dutko
July 1998, Comptes rendus de l'Academie des sciences. Serie III, Sciences de la vie,
M P Wentland, and R B Perni, and P H Dorff, and R P Brundage, and M J Castaldi, and J A Carlson, and T R Bailey, and S C Aldous, and P M Carabateas, and E R Bacon, and R K Kullnig, and D C Young, and M G Woods, and S D Kingsley, and K A Ryan, and D Rosi, and M L Drozd, and F J Dutko
January 2014, Nucleosides, nucleotides & nucleic acids,
M P Wentland, and R B Perni, and P H Dorff, and R P Brundage, and M J Castaldi, and J A Carlson, and T R Bailey, and S C Aldous, and P M Carabateas, and E R Bacon, and R K Kullnig, and D C Young, and M G Woods, and S D Kingsley, and K A Ryan, and D Rosi, and M L Drozd, and F J Dutko
January 2008, Nucleic acids symposium series (2004),
M P Wentland, and R B Perni, and P H Dorff, and R P Brundage, and M J Castaldi, and J A Carlson, and T R Bailey, and S C Aldous, and P M Carabateas, and E R Bacon, and R K Kullnig, and D C Young, and M G Woods, and S D Kingsley, and K A Ryan, and D Rosi, and M L Drozd, and F J Dutko
October 2017, Molecules (Basel, Switzerland),
M P Wentland, and R B Perni, and P H Dorff, and R P Brundage, and M J Castaldi, and J A Carlson, and T R Bailey, and S C Aldous, and P M Carabateas, and E R Bacon, and R K Kullnig, and D C Young, and M G Woods, and S D Kingsley, and K A Ryan, and D Rosi, and M L Drozd, and F J Dutko
October 2020, Molecules (Basel, Switzerland),
Copied contents to your clipboard!